Syngene International yesterday announced the extension of its long-standing multi-discipline research collaboration with Amgen Inc. The contract is currently extended until the end of 2026 and its scope includes integrated drug discovery and development solutions in discovery chemistry and biology, peptide chemistry, antibody and protein reagents, pharmacokinetics and drug metabolism, and pharmaceutical development. In addition to operating the existing Syngene Amgen R&D Center (SARC), under the new contract, Syngene will also build and operate a dedicated laboratory that will enable R&D project acceleration.
Jonathan Hunt, CEO and Managing Director, Syngene International, said, “While SARC was established in 2016, our collaboration with Amgen dates back to 2012. During this time, we have partnered on research and development to address some of the most serious diseases in the world. We have expanded our areas of collaboration, co-authored research papers on novel science and supported the advancement of multiple development projects, while adhering to global standards of quality and safety.”